Critical congenital heart diseases, or CCHDs, are a group of life-threatening structural heart defects present at birth.
Improved SpO 2 Accuracy Now Available for All Patient Populations IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today that RD SET ® sensors with Masimo Measure-through Motion and ...
New Neonatal Study Adds to Body of Clinical Evidence Demonstrating Masimo SET ® Pulse Oximetry’s Unique Ability to Improve Care NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) provides ...
Although current pulse-oximetry technology cannot detect every cardiac defect, the rate of missed CCHD diagnoses is much higher when screening is based on physical examination alone. Health-care ...
Pulse oximetry is a widely used monitoring method for measuring blood oxygen levels and pulse rate. In newborn babies, pulse oximetry can help clinicians conduct screening tests for lung or heart ...
Masimo Corporation MASI received the FDA’s nod for its RD SET sensors to be used with Masimo Measure-through Motion and Low Perfusion SET pulse oximetry. The procedure is aimed at offering improved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results